Hansa Biopharma AB
HNSBF
Rank in Stocks
#14321
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development... Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Share Price
$3.29
Last synced: 2026-11-12
Market Cap
$328.20M
Change (1 day)
0.00%
Change (1 year)
13.06%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Hansa Biopharma AB (HNSBF)
Category
Healthcare
Operating Margin for Hansa Biopharma AB (HNSBF)
Operating Margin as of November 2026 TTM: -194.67%
According to Hansa Biopharma AB's latest financial reports, its current operating margin (TTM) is -194.67%. At the end of 2025 the company had an operating margin of -234.27%.
Operating Margin history for Hansa Biopharma AB from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -194.67% | -16.90% |
| 2025 | -234.27% | -37.08% |
| 2024 | -372.34% | -36.68% |
| 2023 | -588.02% | 57.72% |
| 2022 | -372.83% | -76.59% |
| 2021 | -1,592.72% | -77.15% |
| 2020 | -6,970.76% | -34.42% |
| 2019 | -10,630.05% | 44.81% |
| 2018 | -7,340.62% | 43.49% |
| 2017 | -5,115.72% | 18.72% |
| 2016 | -4,309.23% | 253.72% |
| 2015 | -1,218.27% | 132.52% |
| 2014 | -523.94% | -48.70% |
| 2013 | -1,021.38% | 59.14% |
| 2012 | -641.80% | -133.64% |
| 2011 | 1,907.97% | -524.50% |
| 2010 | -449.46% | -14.80% |
| 2009 | -527.54% | -96.56% |
| 2008 | -15,341.72% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 59.80% | -100.31% |
US
|
|
| 31.60% | -100.16% |
SE
|
|
| 30.13% | -100.15% |
FR
|
|
| 29.76% | -100.15% |
HK
|
|
| 31.11% | -100.16% |
IT
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Hansa Biopharma AB's operating margin
What is Hansa Biopharma AB's operating margin?
Hansa Biopharma AB's operating margin is -194.67%, as of Nov 2026.
What was Hansa Biopharma AB's operating margin in 2025?
In 2025, Hansa Biopharma AB's operating margin was -234.27%, compared with -372.34% in 2024.
How has Hansa Biopharma AB's operating margin changed since 2020?
From 2020 to 2025, Hansa Biopharma AB's operating margin was highest in 2025 (-234.27%) and lowest in 2020 (-6,970.76%).
How does Hansa Biopharma AB's operating margin compare with similar companies?
Hansa Biopharma AB's operating margin (-194.67%) is lower than that of all 5 similar companies listed above. The highest among them is Royalty Pharma plc, with 59.80%.